DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Erdafitinib
Erdafitinib
Systematic Review: Targeting HER2 in Bladder Cancer
Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer
New ADC Shrinks HER2-Positive Tumors
| TIME TRIALS February 2021 Provides You Access to a Network of Just-In-Time Biomarker-Driven Trials for Your Patients
Agents Available Under CTEP Collaborative Agreements for Clinical and Non-Clinical Studies 1 As of 7/28/2021
(Erdafitinib), a Functionally Selective Small Molecule FGFR Family Inhibitor
(Fgfrs): Structures and Small Molecule Inhibitors
New Drug Update
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
New Targets in Endocrine-Resistant Hormone Receptor–Positive Breast Cancer
View of This Manuscript
HAMP - Health Alliance Medical Plan – Commercial
Stembook 2018.Pdf
Precision Oncology Medicines
FGF2-Derived Peptibodyf2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs Into Cancer Cells Overexpressing FGFR1
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Evaluation of Pharmacokinetics, Drug-Likeness, and Medicinal
BALVERSA (Erdafitinib) Tablets, for Oral Use ------ADVERSE REACTIONS------ Initial U.S
Top View
Brain Tumors
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
Oncology Oral, Other Therapeutic Class Review
FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
Administration of Erdafitinib
The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
PDCO Agenda of the 20-23 April 2021 Meeting
Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
Tecentriq® (Atezolizumab)
Informing Treatment Strategies Through a Comprehensive Approach
Fibroblast Growth Factor Receptor Facilitates Recurrence of Minimal Residual Disease Following Trastuzumab Emtansine Therapy
Kinase Inhibitors – Unified Formulary
Pandora's Box: 2019 Oncology and Hematology Drugs
Oncology Agents Policy #: Rx.01.67
Ventegra Overview
Jnj-42756493
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
HUTCHMED (China) Limited Supplemental and Updated Disclosures
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
ATC/DDD Classification (Temporary)
Orange Book Cumulative Supplement 7 July 2021
Oncology Center of Excellence 2019 Annual Report
Game Changers in Pediatric Cancer Jane De Lartigue, Phd
JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Or Refractory Solid Tumors
An Oncology Mouthful: Updates and Pearls for Oral Oncolytics
Real-World Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-Of-One Strategy
Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
The Role of Fibroblast Growth Factor Receptor (FGFR)
Arefyev-Oral Chemotherapy Adverse Events Based On
The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
Download Poster (Pdf)
16722836) Imatinib (Pubmed CID: 123596) in the Treatment of Urothelial Bladder Cancers
FDA Approved Drugs: 2015-2019 12/14/19 Stages of a Drug What Factors FDA Considers During Approval
Leukemia and Lymphoma
Aberrant FGFR Signaling Mediates Resistance to CDK4/6 Inhibitors in ER+ Breast Cancer
409 Oncology Drugs
Overview of 2019 CDER Drug Approvals in Hematology/Oncology
Erdafitinib (Balversa) Reference Number: ERX.SPA.333 Effective Date: 09.01.19 Last Review Date: 08.20 Line of Business: Commercial, Medicaid Revision Log
The Pharmaceutical Industry in 2019. an Analysis of FDA Drug Approvals from the Perspective of Molecules
Erdafitinib (Balversa™) (Updated September 2019)
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Targeted Molecular Therapeutics for Bladder Cancer—A New Option Beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Prior Authorization Criteria
Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: a Work in Progress
BALVERSA® (Erdafitinib) Tablets 1 HIGHLIGHTS of PRESCRIBING
Global Offering
Tyrosine Kinase Receptors in Oncology